期刊
MOLECULES
卷 26, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/molecules26051275
关键词
cystic fibrosis; CFTR; F508del-CFTR; CFTR corrector; CFTR potentiator
资金
- Italian Cystic Fibrosis Research Foundation [4/2018, 6/2019]
Cystic fibrosis is a genetic disease caused by mutations affecting the CFTR chloride channel. Correctors can help overcome the defects in CFTR protein. A new compound has been identified as a potential novel class of CFTR correctors to increase F508del-CFTR activity.
Cystic fibrosis (CF) is a genetic disease caused by mutations that impair the function of the CFTR chloride channel. The most frequent mutation, F508del, causes misfolding and premature degradation of CFTR protein. This defect can be overcome with pharmacological agents named correctors. So far, at least three different classes of correctors have been identified based on the additive/synergistic effects that are obtained when compounds of different classes are combined together. The development of class 2 correctors has lagged behind that of compounds belonging to the other classes. It was shown that the efficacy of the prototypical class 2 corrector, the bithiazole corr-4a, could be improved by generating conformationally-locked bithiazoles. In the present study, we investigated the effect of tricyclic pyrrolothiazoles as analogues of constrained bithiazoles. Thirty-five compounds were tested using the functional assay based on the halide-sensitive yellow fluorescent protein (HS-YFP) that measured CFTR activity. One compound, having a six atom carbocyle central ring in the tricyclic pyrrolothiazole system and bearing a pivalamide group at the thiazole moiety and a 5-chloro-2-methoxyphenyl carboxamide at the pyrrole ring, significantly increased F508del-CFTR activity. This compound could lead to the synthesis of a novel class of CFTR correctors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据